Lieber Orgelbass
Du schreibst:
.........ob Sutent als Folgemedikament nach Nexavar was bringt, ist nicht bekannt. Dazu liegen keinerlei Zahlen vor. Zitat des Urologen "Rational kann man weder einen Wechsel von Nexavar auf Sutent noch ein Beibehalten der Nexavartherapie begründen."...........
Hier ein Text, der Dir antwortet:
Link:
http://kidneycancerassociation.org/K...Cancer2006.pdf
(Text ist auf der zweitletzten Seite)
Costa LJ, Gonzalez M, Breaker K, et al. Sunitinib malate has
activity in advanced RCC previously treated with sorafenib.
Clinical benefits seen with sunitinib and sorafenib are temporary
and therapeutic options are needed for RCC refractory
to these agents. Differences between these two compounds
in terms of targets affected, pharmacokinetics, and toxicity
profiles suggest that cross-resistance may not be universal
and
patients who progressed or were intolerant to one TKI
may benefit from treatment with the other. This retrospective
analysis evaluated patients who had progressive disease
while receiving sorafenib and were subsequently treated with
sunitinib. Since January 2006, 13 patients with progressive
disease (12) or intolerance (1) to treatment with sorafenib
have been treated at the University of Colorado Kidney
Cancer Clinic. Performance status was either 1 or 2 and
median time to progression with sorafenib had been 24.5
weeks. Ten patients have been evaluated for response, 4 had
progressive disease and 6 stable disease as best response.
Although none of the patients obtained a response by RECIST
criteria, 5 of 10 had evidence of a decrease in tumor measurements.
With a median follow-up of 15.3 weeks, median
progression-free survival and overall survival were not
reached. Toxicity was similar to what has previously been
reported with sunitinib.
The authors conclude that sunitinib
has activity in advanced RCC previously treated with sorafenib.
Text wurde von meinem Onkologen bestätigt. Mehr kann ich leider nicht sagen.
Herzlicher Gruss
Urs